Opus TMVR

Mitral valve regurgitation (MR) is a type of heart valve disease in which the valve between the left heart chambers does not close completely, allowing blood to leak backward across the valve. It is the most common type of valvular heart disease. If the leakage is severe, not enough blood will move through the heart and to the rest of the body.

The Opus Transcatheter Mitral Valve Replacement (TMVR) device is designed to treat MR using a transfemoral, transseptal delivery system. The Opus Valve is a self-expanding bioprosthetic valve tethered to an interventricular anchor that can accommodate various annulus sizes and anatomies. Independently adjustable tethers allows the Opus Valve to seal against the native mitral annulus with no paravalvular leakage (PVL) and a low stent profile reduces risk of left ventricular outflow tract (LVOT) obstruction.

Opus is currently in verification & validation testing phase with its TMVR device. Fluoroscopic and echocardiographic imaging of chronic animals confirms good bioprosthetic valve function with no PVL, no LVOT obstruction and normal cardiac function.